Veradermics VDPHL01 Delivers Positive Phase 2 Clinical Trial Results

jondoeuk

Established Member
My Regimen
Reaction score
17
In female pattern hair loss

Today, the company announced positive topline results from its open-label Phase 2 clinical trial (Study ‘207’) evaluating VDPHL01 in females with mild-to-moderate pattern hair loss. More here.

    • Participants achieved an average increase in non-vellus hair counts of 22.7 hairs/cm² and 23.3 hairs/ cm² in once daily and twice daily VDPHL01 4.5mg treatment arms, respectively. So almost a negligible difference, meaning that once daily treatment will likely be sufficient if these results hold in future trials.
    • 88.9% of participants in the once daily dose arm and 90.0% of participants in the twice daily dose arm achieved ‘improved’ or ‘much improved’ hair coverage. These classifications are based on the Androgenetic Alopecia Impact Rating Scale (AAIRS).
    • There were no treatment-related serious adverse events (SAEs) or adverse events of special interest (AESIs) of cardiac origin. They do not mention anything about the most common side effect of oral minoxidil in the form of hirsutism (excess body hair, especially on the face).
    • The ongoing Study ‘306‘ Phase 2/3 trial evaluating VDPHLO1 in females with pattern hair loss has an anticipated 1H 2027 readout date. Female trial enrollment link.
    • They also mention that the topline results from the ongoing Study ‘304‘ second Phase 3 male trial are anticipated in the second half of 2026. Study ‘302‘ topline results for men were released in April 2026.
 
Last edited:

bulli103

Established Member
Reaction score
35
there was a studie before, it doesn't works better than 5 mg minoxidil oral, it's only for people who are afraid about sides, and have too much money.....
 

jondoeuk

Established Member
My Regimen
Reaction score
17
Veradermics announced positive top-line results from Part A of its phase three clinical trial (Study ‘304’). It entailed over 500 males with mild-to-moderate pattern hair loss who took oral VDPHL01 (extended-release oral minoxidil). https://finance.yahoo.com/healthcare/articles/veradermics-phase-iii-hair-loss-170221319.html

In Part A of Study '304', VDPHL01 achieved superior hair growth compared with placebo when it comes to non-vellus Target Area Hair Count (TAHC). After six months, participants achieved an average increase in non-vellus hair count of 28.6 hairs/cm² and 36.4 hairs/cm² in once-daily and twice-daily VDPHL01 treatment arms, respectively. Those receiving placebo showed a 6.6 hairs/cm² increase from baseline at month six.

These results are similar to findings from Study '302' in April 26, 2026. The numbers there were an increase of 30.3 hairs/cm² and 33.0 hairs/cm² in once daily and twice daily VDPHL01 treatment arms. https://www.dermatologytimes.com/vi...air-growth-outcomes-in-male-pattern-hair-loss

It almost looks certain that Veradermics' VDPHL01 and Cosmo Pharmaceuticals' Clascoterone will become the third and fourth hair loss drugs ever approved by the US FDA. After topical Minoxidil (in 1988) and oral Finasteride (in 1997).
 

bulli103

Established Member
Reaction score
35
It is safer. It looks to be more effective as well.
it's not more effective, there are studies out about, also no reason why it should be......minoxidil oral is at the market for more than 50 years, how many deads since then ?... don' t belive everything you read
it's for our hypochondriacs, that's all...
 

jondoeuk

Established Member
My Regimen
Reaction score
17
it's not more effective, there are studies out about, also no reason why it should be......minoxidil oral is at the market for more than 50 years, how many deads since then ?... don' t belive everything you read
it's for our hypochondriacs, that's all...
I said it looks to be more effective, not that it is.

Standard oral minoxidil dissolves and absorbs quickly, causing a sharp blood concentration spike within about an hour that largely clears within four hours. VDPHL01 slowly dissolves over hours to provide a steady, extended release. VDPHL01 delivers nearly twice the total minoxidil exposure over twelve hours compared to standard doses while keeping plasma levels above the hair growth threshold for far longer.

VDPHL01 blunts peak concentration to stay below cardiac safety thresholds, unlike standard oral minoxidil (that carries a boxed warning). https://pubmed.ncbi.nlm.nih.gov/36117778/ https://pubmed.ncbi.nlm.nih.gov/36267649/ https://pubmed.ncbi.nlm.nih.gov/38598226/

Lowering peak concentrations does not eliminate all systemic side effects. Fluid retention (ankle/leg swelling) and hypertrichosis (unwanted body hair growth) still occur with VDPHL01, but both at a low rate.
 
Last edited:
Top